YFRM Technologies, Inc. Completes Acquisition of the Integrative Stem Cell Institute

Marketwired

PITTSTON, ME--(Marketwired - May 21, 2013) - YaFarm Technologies, Inc. (PINKSHEETS: YFRM) (YaFarm) is pleased to announce the completion of its acquisition of the Integrative Stem Cell Institute (the ISCI). The new company, to be called "the Integrative Stem Cell Institute," will continue the pioneering work of the ISCI in the field of cell-based regenerative medicine. The ISCI will be housed in Cancun's Hospital Galenia and will combine a world-class medical facility with a state-of-the-art laboratory in the investigational treatments of patients with chronic and degenerative diseases as part of controlled clinical studies.

The new company will provide point-of-care therapies based upon cell-based, regenerative medicine. The company will focus on the treatment of patients with limited or no options, and who suffer from diseases for which current medicine provides little or no alleviation. The ISCI combines a state-of-the-art, ISO 7 laboratory with cell-based treatments and nutritional, occupational, physical and hyperbaric oxygen therapies to provide a unique and highly integrative medical approach.

Juan Castillo, MD, founder of the ISCI, said, "Combining these two companies has allowed the ISCI to advance quickly into a global leadership position in this emerging field. Regenerative medicine is the future of patient care." Dr. Castillo continued, "Physicians from around the world have used stem cells to treat thousands of patients with diseases such as MS, Parkinson's and autism. Our methods, combined with an interdisciplinary team of physicians, provide a new benchmark for quality patient care."

YaFarm has requested shares of its stock be issued to members of the ISCI management, which will give them controlling interest, and made arrangements for delivery of books and records. As a result of the transaction, Brian Hermenze and Cody McDowell have resigned from the Board and as President and Chief Executive Officer. Dr. Juan Casteel, Elizabeth Casteel, and David Kugelman have been appointed to the Board of Directors.

About Integrative Stem Cell Institute (ISCI)
The Integrative Stem Cell Institute (ISCI) is a premier provider of point-of-care, stem cell-based therapies for patients from around the world. With a state of the art laboratory housed within the Hospital Galenia in Cancun, Mexico, the ISCI combines the most advanced scientific application of stem cells with second to none medical care within the structure of adaptive clinical trials to effectively track long term outcomes and assure patient safety.

More information on The Integrative Stem Cell Institute is available on the company's website at www.iscelli.com.

SAFE HARBOR STATEMENT

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition, adequate financing, and other material risks. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance, or achievements to be materially different from the statements made herein.

Contact:


The Integrative Stem Cell Institute
Miranda Abrahams
Miranda@iscelli.com

Investor Contact
Atlanta Capital Partners, LLC
David Kugelman
(866) 692-6847
info@atlcp.com

View Comments (0)